MSF Field Research > 1 Published Research and Commentary > Leishmaniasis/Kala Azar > High mortality among older patients treated with pentavalent antimonials for visceral leishmaniasis in East Africa and rationale for switch to liposomal amphotericin B

Please use this identifier to cite or link to this item: http://hdl.handle.net/10144/120107
    Del.icio.us     LinkedIn     Citeulike     Connotea     Facebook     Stumble it!


Download this article:
View/Open File Description Size Format
Thumbnail
View/Open
101115_Chappuis_VL-45yo-high-mort-SSG_AAC-2010_LETTER_in-press.pdfMain article236KbAdobe PDF

Title: High mortality among older patients treated with pentavalent antimonials for visceral leishmaniasis in East Africa and rationale for switch to liposomal amphotericin B
Authors: Chappuis, François
Alirol, Emilie
Worku, Dagemlidet T
Mueller, Yolanda
Ritmeijer, Koert
Affiliation: Médecins Sans Frontières, Geneva, Switzerland; Médecins Sans Frontières, Amsterdam, The Netherlands
Citation: Antimicrob Agents Chemother, published online ahead of print on 15 November 2010
Journal: Antimicrobial Agents and Chemotherapy
Issue Date: 15-Nov-2010
URI: http://hdl.handle.net/10144/120107
DOI: 10.1128/AAC.01298-10
PubMed ID: 21078947
Additional Links: http://aac.asm.org/cgi/content/abstract/AAC.01298-10v1
Abstract: Visceral leishmaniasis (VL; kala azar), a fatal disease if left untreated, is one of the most neglected tropical diseases....
Type: Article
Language: en
MeSH: Kala Azar
Visceral Leishmaniasis
Black Fever
Eastern Africa
Sudan
Uganda
Ethiopia
Antimony
Antimony Sodium Gluconate
Sodium Stibogluconate
Liposomal Amphotericin B
AmBisome
Adult
Middle Aged
Mortality
ISSN: 1098-6596
Rights: Published by American Society for Microbiology Archived on this site with permission and copyright by the American Society for Microbiology
Appears in topics: Leishmaniasis/Kala Azar

Related articles on PubMed
bullet
bullet
[Liposomal amphotericin B as treatment for visceral leishmaniasis in Europe, 2009].
Rosenthal E, Delaunay P, Jeandel PY, Haas H, Pomares-Estran C, Marty P
2009 Oct
bullet
Liposomal amphotericin B for the treatment of visceral leishmaniasis.
Bern C, Adler-Moore J, Berenguer J, Boelaert M, den Boer M, Davidson RN, Figueras C, Gradoni L, Kafetzis DA, Ritmeijer K, Rosenthal E, Royce C, Russo R, Sundar S, Alvar J
2006 Oct 1
bullet
Liposomal amphotericin B in the treatment of visceral leishmaniasis in immunocompromised patients.
Vigna E, De Vivo A, Gentile M, Morelli R, Lucia E, Mazzone C, Recchia AG, Vianelli N, Morabito F
2010 Oct
bullet
Drug regimens for visceral leishmaniasis in Mediterranean countries.
Gradoni L, Soteriadou K, Louzir H, Dakkak A, Toz SO, Jaffe C, Dedet JP, Campino L, Cañavate C, Dujardin JC
2008 Oct
See all 106 articles

All Items in MSF are protected by copyright, with all rights reserved, unless otherwise indicated.

 

OR Logo Powered by Open Repository | Cookies

My MSF

MSF logo MSF Field Research

Nov 24, 2014